Phase 3 Interim Result Below Continuation Threshold
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Operational challenges led to significant missing data, impacting the interim results, and the company is currently reviewing the data to understand these effects. Paradigm has requested a voluntary suspension of its securities while it assesses the financial implications of this outcome and discusses funding arrangements. The Board expressed disappointment over the trial results and will provide further updates as more information becomes available.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Suspension from Quotation
- Appendix 4E and 2026 Annual Report
- June 2026 Quarterly Activities Report & Appendix 4C
- Paradigm Receives $5.75m R&D Tax Incentive Refund
- Drawdown of Tranche 4 under the Convertible Note Facility
Later from Paradigm Biopharmaceuticals
- Agreement to Return US$2M to Obsidian
- Continuation of Voluntary Suspension
- Board Initiates Voluntary Administration
- Appointment of Voluntary Administrators
- Continuation of Suspension from Quotation
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals